Published in J Natl Cancer Inst on June 17, 1998
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res (2010) 1.74
Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation (2008) 1.55
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res (2003) 1.23
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
New insights into the tumor suppression function of P27(kip1) Proc Natl Acad Sci U S A (1998) 1.17
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc (2011) 1.12
Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol (1999) 1.08
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol (2002) 1.06
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol (2010) 0.92
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology (2010) 0.90
Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer (1999) 0.88
XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1). Prostate (2011) 0.87
The role of the ubiquitin-proteasome system in kidney diseases. Clin Exp Nephrol (2012) 0.85
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett (2013) 0.83
Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays. Hum Pathol (2011) 0.82
Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr Cancer (2010) 0.82
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review. Acta Otorhinolaryngol Ital (2005) 0.81
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. J Negat Results Biomed (2012) 0.78
Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer (2011) 0.78
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget (2015) 0.78
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget (2016) 0.75
Tissue microarrays in prostate cancer research. Rev Urol (2004) 0.75
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature (2001) 6.62
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
The galvanization of biology: a growing appreciation for the roles of zinc. Science (1996) 5.67
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A (1997) 4.71
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
YY1 is an initiator sequence-binding protein that directs and activates transcription in vitro. Nature (1991) 4.30
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Food and metabolic signalling defects in a Caenorhabditis elegans serotonin-synthesis mutant. Nature (2000) 4.01
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
Structural basis of IAP recognition by Smac/DIABLO. Nature (2001) 3.66
Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (2000) 3.54
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc Natl Acad Sci U S A (1993) 3.09
Structural basis of caspase-7 inhibition by XIAP. Cell (2001) 2.99
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature (1999) 2.95
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev (1995) 2.93
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A (2001) 2.83
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell (1996) 2.66
Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol (1999) 2.61
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell (2001) 2.39
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33
The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol (1995) 2.32
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ (2006) 2.25
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Determinants of specificity in TGF-beta signal transduction. Genes Dev (1998) 2.23
Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg (2001) 2.21
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
The AKT kinase is activated in multiple myeloma tumor cells. Blood (2001) 2.20
Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest (2001) 2.20
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum (1999) 2.18
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18
Displacement of BrdUrd-induced YY1 by serum response factor activates skeletal alpha-actin transcription in embryonic myoblasts. Proc Natl Acad Sci U S A (1992) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Yin-yang 1 activates the c-myc promoter. Mol Cell Biol (1993) 2.06
HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol (1987) 2.04
Coexisting stable conformations of gaseous protein ions. Proc Natl Acad Sci U S A (1993) 2.03
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol (1989) 1.96
Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell (2001) 1.95
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1.93
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
The 1.9 A crystal structure of Escherichia coli MurG, a membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci (2000) 1.90
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol (1995) 1.89
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Expression of ras proto-oncogene proteins in normal human tissues. Oncogene (1987) 1.86
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. Proc Natl Acad Sci U S A (2000) 1.82
Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem (2001) 1.82
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ (2012) 1.81
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75
MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene (2012) 1.74
Size dependence of Young's modulus in ZnO nanowires. Phys Rev Lett (2006) 1.74